Tandem Diabetes Care (Nasdaq:TNDM) shares ticked up today after Wells Fargo declared it “Equal Weight,” an improvement from “Underweight.” Shares of TNDM rose 8.3% at $42.81 apiece in midday trading today. MedTech 100 Index — which includes stocks of the world’s largest medical device companies — ticked up 6.8%. According to a report from SeekingAlpha, […]
Tandem Diabetes Care
Study supports Tandem t:slim X2 insulin pump for type 2 diabetes
Tandem Diabetes Care (Nasdaq:TNDM) announced that a study of adults with type 2 diabetes supported its automated insulin delivery system. The study evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology. Patients achieved improvement in all clinical endpoints with the technology, which currently does not hold approval for type […]
Tandem stock dives on Q3 misses, reduced guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a big hit after hours on third-quarter results that missed the consensus forecast. Shares of TNDM. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.3%. The San Diego-based company posted losses of nearly $49 million for the […]
Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
Tandem Diabetes Care (Nasdaq:TNDM) announced today that its users have delivered more than 1 million insulin boluses using its app. Users of the t:connect app feature on their mobile devices have reached the 1 million insulin bolus milestone with the t:slim X2 insulin pump within the first month following its commercial release. San Diego-based Tandem […]
Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
Wells Fargo downgraded Tandem Diabetes Care (Nasdaq:TNDM) as competitors apply pressure to the automated insulin delivery technology developer. According to SeekingAlpha, analysts led by Larry Biegelsen moved Tandem from “Overweight” to “Underweight” due to bullish expectations on Wall Street as the company’s competition, including Insulet and Medtronic, come to the fore. The street responded in kind, with […]
Tandem sinks on Q2 misses, slashed sales guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a bit hit after hours on second-quarter results that missed the consensus forecast. Shares of TNDM were down 7.2% at $64 per share after the market closed, which was when it released its quarterly results. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device […]
Tandem Diabetes Care acquires infusion set maker Capillary Biomedical
Tandem Diabetes Care (Nasdaq:TNDM) announced that it acquired infusion set developer Capillary Biomedical. San Diego-based Tandem, a global insulin delivery and diabetes technology company, announced its intention to acquire Irvine, California-based Capillary last week. Financial terms for the deal were not disclosed. “Infusion sets provide people flexible options in insulin pump wearability, and we are […]
Tandem Diabetes Care adds two new members to its board
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it appointed two new independent members to its board of directors. Myoung Cha and Joao Malagueira have been named to the San Diego-based automated insulin delivery technology developer’s board, effective yesterday. “We welcome Joao and Myoung to our board of directors at this exciting stage in Tandem’s evolution,” […]
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott, Insulet and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. […]
Dexcom CEO expects ‘science boom’ with CGM, automated insulin delivery
With the G7 nearing FDA clearance, Dexcom leadership foresees major innovations for integrated automated insulin delivery down the line. Kevin Sayer began thinking about automated insulin delivery all the way back in 1994 when he was working at MiniMed. Nearly 30 years later, as CEO of Dexcom (Nasdaq:DXCM), that space continues to pique his interest. […]
